Teladoc Health (NYSE:TDOC) PT Lowered to $25.00

Teladoc Health (NYSE:TDOC) had its price objective decreased by Canaccord Genuity Group from $28.00 to $25.00 in a research note issued to investors on Friday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the health services provider’s stock.

A number of other equities analysts also recently commented on the stock. DA Davidson reduced their price objective on shares of Teladoc Health from $22.00 to $18.00 and set a neutral rating for the company in a report on Wednesday, February 21st. Piper Sandler reduced their price objective on shares of Teladoc Health from $30.00 to $25.00 and set an overweight rating for the company in a report on Wednesday, February 21st. SVB Leerink initiated coverage on shares of Teladoc Health in a report on Monday, February 26th. They set a market perform rating and a $17.00 price objective for the company. Truist Financial reduced their price objective on shares of Teladoc Health from $23.00 to $17.00 and set a hold rating for the company in a report on Wednesday, March 6th. Finally, Barclays cut their price target on shares of Teladoc Health from $26.00 to $25.00 and set an overweight rating for the company in a report on Wednesday, February 21st. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of Hold and an average price target of $19.67.

Teladoc Health Price Performance

NYSE:TDOC opened at $13.01 on Friday. Teladoc Health has a 1 year low of $12.65 and a 1 year high of $30.41. The firm’s fifty day simple moving average is $15.01 and its 200 day simple moving average is $17.77. The company has a current ratio of 3.54, a quick ratio of 3.47 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company had revenue of $646.13 million during the quarter, compared to the consensus estimate of $637.31 million. During the same period last year, the company earned ($0.37) earnings per share. Teladoc Health’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, sell-side analysts expect that Teladoc Health will post -1.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jason N. Gorevic sold 53,755 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $780,522.60. Following the completion of the sale, the chief executive officer now owns 653,073 shares of the company’s stock, valued at $9,482,619.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Jason N. Gorevic sold 53,755 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $780,522.60. Following the completion of the transaction, the chief executive officer now owns 653,073 shares of the company’s stock, valued at $9,482,619.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Richard J. Napolitano sold 3,765 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the completion of the transaction, the chief accounting officer now directly owns 18,077 shares of the company’s stock, valued at approximately $262,478.04. The disclosure for this sale can be found here. Insiders sold 135,441 shares of company stock valued at $2,038,251 over the last quarter. 1.63% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TDOC. ARK Investment Management LLC increased its stake in shares of Teladoc Health by 4.5% in the fourth quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock valued at $457,389,000 after buying an additional 912,692 shares during the period. Vanguard Group Inc. increased its position in Teladoc Health by 11.8% during the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after purchasing an additional 1,855,480 shares during the period. Dimensional Fund Advisors LP increased its position in Teladoc Health by 25.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock valued at $82,636,000 after purchasing an additional 767,999 shares during the period. Charles Schwab Investment Management Inc. increased its position in Teladoc Health by 6.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,654,116 shares of the health services provider’s stock valued at $35,646,000 after purchasing an additional 104,531 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Teladoc Health by 9.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 658,435 shares of the health services provider’s stock valued at $12,240,000 after purchasing an additional 57,989 shares during the period. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.